548 related articles for article (PubMed ID: 8057673)
21. Mutational Spectrum of Fanconi Anemia Associated Myeloid Neoplasms.
Chao MM; Thomay K; Goehring G; Wlodarski M; Pastor V; Schlegelberger B; Schindler D; Kratz CP; Niemeyer C
Klin Padiatr; 2017 Nov; 229(6):329-334. PubMed ID: 29132164
[TBL] [Abstract][Full Text] [Related]
22. Mutations in the P53 and RAS family genes are associated with tumor progression of BCR/ABL negative chronic myeloproliferative disorders.
Gaidano G; Guerrasio A; Serra A; Carozzi F; Cambrin GR; Petroni D; Saglio G
Leukemia; 1993 Jul; 7(7):946-53. PubMed ID: 8321046
[TBL] [Abstract][Full Text] [Related]
23. Genetic predisposition syndromes: when should they be considered in the work-up of MDS?
Babushok DV; Bessler M
Best Pract Res Clin Haematol; 2015 Mar; 28(1):55-68. PubMed ID: 25659730
[TBL] [Abstract][Full Text] [Related]
24. Genetic reversion in an acute myelogenous leukemia cell line from a Fanconi anemia patient with biallelic mutations in BRCA2.
Ikeda H; Matsushita M; Waisfisz Q; Kinoshita A; Oostra AB; Nieuwint AW; De Winter JP; Hoatlin ME; Kawai Y; Sasaki MS; D'Andrea AD; Kawakami Y; Joenje H
Cancer Res; 2003 May; 63(10):2688-94. PubMed ID: 12750298
[TBL] [Abstract][Full Text] [Related]
25. Multiple point mutation of N-ras and K-ras oncogenes in myelodysplastic syndrome and acute myelogenous leukemia.
Nakagawa T; Saitoh S; Imoto S; Itoh M; Tsutsumi M; Hikiji K; Nakamura H; Matozaki S; Ogawa R; Nakao Y
Oncology; 1992; 49(2):114-22. PubMed ID: 1574246
[TBL] [Abstract][Full Text] [Related]
26. Fanconi anemia and the development of leukemia.
Alter BP
Best Pract Res Clin Haematol; 2014; 27(3-4):214-21. PubMed ID: 25455269
[TBL] [Abstract][Full Text] [Related]
27. Acute myeloid leukemia: analysis of ras gene mutations and clonality defined by polymorphic X-linked loci.
Bartram CR; Ludwig WD; Hiddemann W; Lyons J; Buschle M; Ritter J; Harbott J; Fröhlich A; Janssen JW
Leukemia; 1989 Apr; 3(4):247-56. PubMed ID: 2564452
[TBL] [Abstract][Full Text] [Related]
28. The presence of clonal cell subpopulations in peripheral blood and bone marrow of patients with refractory cytopenia with multilineage dysplasia but not in patients with refractory anemia may reflect a multistep pathogenesis of myelodysplasia.
Cermák J; Belicková M; Krejcová H; Michalová K; Zilovcová S; Zemanová Z; Brezinová J; Sieglová Z
Leuk Res; 2005 Apr; 29(4):371-9. PubMed ID: 15725470
[TBL] [Abstract][Full Text] [Related]
29. Molecular pathways mediating MDS/AML with focus on AML1/RUNX1 point mutations.
Harada Y; Harada H
J Cell Physiol; 2009 Jul; 220(1):16-20. PubMed ID: 19334039
[TBL] [Abstract][Full Text] [Related]
30. N-ras mutation and karyotypic evolution are closely associated with leukemic transformation in myelodysplastic syndrome.
Horiike S; Misawa S; Nakai H; Kaneko H; Yokota S; Taniwaki M; Yamane Y; Inazawa J; Abe T; Kashima K
Leukemia; 1994 Aug; 8(8):1331-6. PubMed ID: 8057669
[TBL] [Abstract][Full Text] [Related]
31. Retrospective analysis of ras gene activation in myeloid leukemic cells.
Lübbert M; Jonas D; Miller CW; Herrmann F; Mertelsmann R; McCormick F; Koeffler HP
Oncogene; 1990 Apr; 5(4):583-7. PubMed ID: 2183160
[TBL] [Abstract][Full Text] [Related]
32. Molecular genetic aspects of myelodysplastic syndromes.
Bartram CR
Hematol Oncol Clin North Am; 1992 Jun; 6(3):557-70. PubMed ID: 1613006
[TBL] [Abstract][Full Text] [Related]
33. N-RAS gene mutation in patients with aplastic anemia and aplastic anemia/ paroxysmal nocturnal hemoglobinuria during evolution to clonal disease.
Mortazavi Y; Tooze JA; Gordon-Smith EC; Rutherford TR
Blood; 2000 Jan; 95(2):646-50. PubMed ID: 10627475
[TBL] [Abstract][Full Text] [Related]
34. Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia.
Shih LY; Huang CF; Wang PN; Wu JH; Lin TL; Dunn P; Kuo MC
Leukemia; 2004 Mar; 18(3):466-75. PubMed ID: 14737077
[TBL] [Abstract][Full Text] [Related]
35. Primitive hematopoietic stem cells shows a polyclonal pattern in myelodysplastic syndromes.
Guidetti F; Grazioli S; Capelli F; Marini C; Gallicchio M; De Micheli D; Castello L; Sainaghi PP; Fra GP; Saglio G; Avanzi GC
Haematologica; 2004 Jan; 89(1):21-8. PubMed ID: 14754602
[TBL] [Abstract][Full Text] [Related]
36. [Molecular abnormalities and clonality in myelodysplastic syndromes].
Fenaux P; Preudhomme C
Pathol Biol (Paris); 1997 Sep; 45(7):556-60. PubMed ID: 9404479
[TBL] [Abstract][Full Text] [Related]
37. Structural integrity and expression of the L3MBTL gene in normal and malignant hematopoietic cells.
MacGrogan D; Kalakonda N; Alvarez S; Scandura JM; Boccuni P; Johansson B; Nimer SD
Genes Chromosomes Cancer; 2004 Nov; 41(3):203-13. PubMed ID: 15334543
[TBL] [Abstract][Full Text] [Related]
38. Nuclear phospholipase C β1 signaling, epigenetics and treatments in MDS.
Follo MY; Marmiroli S; Faenza I; Fiume R; Ramazzotti G; Martelli AM; Gobbi P; McCubrey JA; Finelli C; Manzoli FA; Cocco L
Adv Biol Regul; 2013 Jan; 53(1):2-7. PubMed ID: 23058275
[TBL] [Abstract][Full Text] [Related]
39. [Activation of ras oncogene in myelodysplastic syndrome and acute myelogenous leukemia].
Hirai H; Hirano N; Yazaki Y
Gan To Kagaku Ryoho; 1991 Jun; 18(7):1090-7. PubMed ID: 2053767
[TBL] [Abstract][Full Text] [Related]
40. Apoptosis, bcl-2 expression and p53 accumulation in myelodysplastic syndrome, myelodysplastic-syndrome-derived acute myelogenous leukemia and de novo acute myelogenous leukemia.
Kurotaki H; Tsushima Y; Nagai K; Yagihashi S
Acta Haematol; 2000; 102(3):115-23. PubMed ID: 10692673
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
